Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS: We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS: and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS: We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“LBCL is genetically and biologically heterogeneous. This diversity includes both tumor and the corresponding tumor microenvironment (TME), and it affects response to standard immunochemotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationRosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationA loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationInhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Self-citationChalla-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
Cited by
Items 701–800 of 1,000
Gallman, A. E., Wolfreys, F. D., Nguyen, D. N., Sandy, M., Xu, Y., An, J., Li, Z., Marson, A., Lu, E., & Cyster, J. G. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg1101 · Cited by 18
The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Nuvvula, S., Dahiya, S., & Patel, S. A. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.010 · Cited by 18
Classifying Germinal Center Derived Lymphomas—Navigate a Complex Transcriptional Landscape
Loeffler‐Wirth, H., Kreuz, M., Schmidt, M., Ott, G., Siebert, R., & Binder, H. (2022) · Cancers · doi:10.3390/cancers14143434 · Cited by 18
Self-citationMinimal information for reporting a genomics experiment
Dreval, K., Boutros, P. C., & Morin, R. D. (2022) · Blood · doi:10.1182/blood.2022016095 · Cited by 18
Nanoplasmonic biosensors for precision medicine
Xiao, Y., Zhang, Z., Yin, S., & Ma, X. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1209744 · Cited by 18
Hepatitis B Virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities
Rosenberg, M. C., Poluch, M. L., Thomas, C. J., Sindaco, P., Khoo, A. S. B., & Porcu, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1275800 · Cited by 18
Bibas, M. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.007 · Cited by 18
Dogliotti, I., Peri, V., Clerico, M., Vassallo, F., Musto, D., Mercadante, S., Ragaini, S., Botto, B., Levis, M., Novo, M., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7448 · Cited by 18
Narkhede, M. S., Tomassetti, S., Iqbal, M., Tin, A. S., Rivero-Hinojosa, S., George, G. V., Widden, H., Benrud, R., Malhotra, M., Rodriguez, A. A., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1407003 · Cited by 18
Identification of genetic subtypes in follicular lymphoma
Shelton, V., Detroja, R., Liu, T., Isaev, K., Silva, A., Passerini, V., Bakhtiari, M., Calvente, L., Hong, M., He, M. Y., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01111-w · Cited by 18
Self-citationGöbel, C., Niccolai, R., de Groot, M. H. P., Jayachandran, J., Traets, J. J. H., Kloosterman, D. J., Gregoricchio, S., Morris, B., Kreft, M., Song, J., et al. (2025) · Blood · doi:10.1182/blood.2024025500 · Cited by 18
Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma
Nguyen, V. T. M., Namba, H., Porter, H., Shlyueva, D., López, E., Melcher, A. A., Béguelin, W., Melnick, A. M., & Helin, K. (2025) · Blood · doi:10.1182/blood.2024026534 · Cited by 18
Cvetković, Z., Marković, O., Marinković, G., Pejić, S., & Vučić, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125670 · Cited by 18
Yoon, S. E., Kim, W. S., & Kim, S. J. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.396 · Cited by 18
Jabłońska, E., Białopiotrowicz, E., Szydłowski, M., Prochorec‐Sobieszek, M., Juszczyński, P., & Szumera‐Ciećkiewicz, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.07.005 · Cited by 18
Davis, A. R., Stone, S. L., Oran, A. R., Sussman, R. T., Bhattacharyya, S., Morrissette, J. J. D., & Bagg, A. (2020) · Modern Pathology · doi:10.1038/s41379-020-00720-7 · Cited by 18
Targeting epigenetic mechanisms to overcome venetoclax resistance
Prado, G., Kaestner, C. L., Licht, J. D., & Bennett, R. L. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119047 · Cited by 18
Wang, L., Guan, W., & Peng, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.676792 · Cited by 18
NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma
Feng, L., Xu, X., & Zhao, K. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106708 · Cited by 18
Hayakawa, J., Seki, T., Kawazoe, Y., & Ohe, K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269570 · Cited by 18
Rovsing, A. B., Thomsen, E. A., Nielsen, I. H., Skov, T. W., Luo, Y., Dybkær, K., & Mikkelsen, J. G. (2023) · British Journal of Haematology · doi:10.1111/bjh.18872 · Cited by 18
Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax
Zhu, F., Crombie, J. L., Wei Min, N. I., Hoang, N.-M., Garg, S., Hackett, L. R., Chong, S. J. F., Collins, M. C., Rui, L., Griffin, J. D., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283245 · Cited by 18
Ochi, Y., Hiramoto, N., Yoshizato, T., Ono, Y., Takeda, J., Shiozawa, Y., Yoshida, K., Kakiuchi, N., Shiraishi, Y., Tanaka, H., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.193490 · Cited by 18
Perfecto‐Avalos, Y., García, A., Hernandez-Reynoso, A. G., Sanchez‐Ante, G., Ortíz-Hidalgo, C., Scott, S., Fuentes-Aguilar, R. Q., Díaz-Domínguez, R., León-Martínez, G., Velasco-Vales, V., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1951-y · Cited by 18
Chen, Z., Zou, Y., Liu, W., Guan, P., Tao, Q., Xiang, C., Zhang, W., Ye, Y., Yan, J., & Zhao, S. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001386 · Cited by 18
Sparano, J. A., Lee, J. Y., Kaplan, L. D., Ramos, J. C., Ambinder, R. F., Wachsman, W., Aboulafia, D. M., Noy, A., Henry, D. H., Ratner, L., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.243386 · Cited by 18
Recent advances in upper gastrointestinal lymphomas: molecular updates and diagnostic implications
Foukas, P. G., Bisig, B., & de Leval, L. (2020) · Histopathology · doi:10.1111/his.14289 · Cited by 18
Xie, Y., Luo, X., He, H., Pan, T., & He, Y. (2021) · Cancer Medicine · doi:10.1002/cam4.3859 · Cited by 18
Magistri, M., Happ, L. E., Ramdial, J., Lu, X., Stathias, V., Kunkalla, K., Agarwal, N., Jiang, X., Schürer, S. C., Dubovy, S. R., et al. (2021) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0022 · Cited by 18
Albitar, M. X., Zhang, H., Goy, A. H., Xu-Monette, Z. Y., Bhagat, G., Visco, C., Tzankov, A., Fang, X., Zhu, F., Dybkær, K., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00617-5 · Cited by 18
Chromatin-Remodeled State in Lymphoma
Liu, Y., Gonzalez, Y., & Amengual, J. E. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00541-9 · Cited by 17
Kozaki, R., Yasuhiro, T., Kato, H., Murai, J., Hotta, S., Ariza, Y., Sakai, S., Fujikawa, R., & Yoshida, T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282166 · Cited by 17
Turi, M., Sithara, A. A., Hofmanová, L., Žihala, D., Radhakrishnan, D., Vdovin, A., Knápková, S., Ševčíková, T., Chyra, Z., Jelínek, T., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065623 · Cited by 17
Pathology and new insights in central nervous system lymphomas
Lebrun, L., Allard-Demoustiez, S., & Salmon, I. J. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000978 · Cited by 17
Davies, J. R., Hilton, L. K., Jiang, A., Barrans, S., Burton, C. H., Johnson, P., Davies, A. J., Du, M., Tooze, R. M., Cucco, F., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010673 · Cited by 17
Geng, H., Jia, S., Zhang, Y., Li, J., Yang, Q., Zeng, L., Zong, X., Lu, Y., Lu, S., Zhou, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1219167 · Cited by 17
McCrury, M., Swafford, K., Shuttleworth, S. L., Mehdi, S. H., Acharya, B., Saha, D., Naceanceno, K. S., Byrum, S. D., Storey, A. J., Xu, Y.-Z., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0299 · Cited by 17
Zaccaria, G. M., Altini, N., Mezzolla, G., Vegliante, M. C., Stranieri, M., Pappagallo, S. A., Ciavarella, S., Guarini, A., & Bevilacqua, V. (2023) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2023.107966 · Cited by 17
Chua, B. J. G., Low, C. E., Yau, C. E., Tan, Y. H., Chiang, J., Chang, E. W. Y., Chan, J. Y., Poon, E. Y. L., Somasundaram, N., Rashid, M. F. H., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00467-2 · Cited by 17
Xiong, D., Geng, C., Zeng, L., Yao, H., Tan, J., Zhang, L., Liu, X., & Liu, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28584 · Cited by 17
Self-citationEhinger, M., & Béné, M. C. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03819-3 · Cited by 17
Frontzek, F., Renaud, L., Dührsen, U., Poeschel, V., Bernard, S., Chartier, L., Ketterer, N., Récher, C., Fitoussi, O., Held, G., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02371-y · Cited by 17
Self-citationSoscia, R., Assanto, G. M., Starza, I. D., Moia, R., Talotta, D., Bellomarino, V., Bellissimo, T., Antonacci, M., Petrucci, L., Gaïdano, G., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.286331 · Cited by 17
Practical microenvironment classification in diffuse large B cell lymphoma using digital pathology
Wang, Y., Wang, S., Yi, H., Qian, Y., Wang, Y., Xu, H., Xu-Monette, Z. Y., Au, K., Tian, S., Dong, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102030 · Cited by 17
Frontzek, F., & Lenz, G. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1683447 · Cited by 17
Wise, J. F., Nakken, S., Steen, C. B., Vodák, D., Trøen, G., Johannessen, B., Lingjærde, O. C., Hilden, V. I., Blaker, Y. N., Bai, B., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001325 · Cited by 17
Yasuda, T., Sanada, M., Nishijima, D., Kanamori, T., Iijima, Y., Hattori, H., Saito, A. M., Miyoshi, H., Ishikawa, Y., Asou, N., et al. (2020) · Cancer Science · doi:10.1111/cas.14552 · Cited by 17
Norrington, M., Rathi, N., Jenkinson, M. D., & Mills, S. J. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.05.038 · Cited by 17
Sartori, G., Napoli, S., Cascione, L., Chung, E. Y., Priebe, V., Arribas, A. J., Mensah, A. A., Dall’Angelo, M., Falzarano, C., Barnabei, L., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02159-3 · Cited by 17
Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms
Dumontet, E., Mancini, S. J. C., & Tarte, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.784691 · Cited by 17
Clinical Features and Prognostic Significance of NOTCH1 Mutations in Diffuse Large B-Cell Lymphoma
Li, Z., Yu, F., Ye, W., Mao, L., Huang, J., Shao, Y., Yan, J., Yu, W., Jin, J., & Wang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.746577 · Cited by 17
Self-citationCorinaldesi, C., Holmes, A. B., Shen, Q. “., Grunstein, E., Pasqualucci, L., Dalla‐Favera, R., & Basso, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.818758 · Cited by 17
Guo, D., Hong, L., Ji, H., Jiang, Y., Lu, L., Wang, X., & Huang, H. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s341355 · Cited by 17
Carrión, N. P., Martín, A., Nogales‐Fernández, E., Jiménez‐Cortegana, C., Carnicero-González, F., Ríos, E., de la Cruz‐Vicente, F., Rodríguez‐García, G., Fernández-Álvarez, R., Martínez-Banaclocha, N., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0588 · Cited by 17
The X-Linked Helicase DDX3X Is Required for Lymphoid Differentiation and MYC-Driven Lymphomagenesis
Lacroix, M., Beauchemin, H., Fraszczak, J., Ross, J., Shooshtarizadeh, P., Chen, R., & Möröy, T. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2454 · Cited by 17
Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies
Deshpande, A. J., & Munoz, J. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.948513 · Cited by 17
Recent advances in the diagnosis and the treatment of primary CNS lymphoma
Rachdi, A., Hernández-Tost, H., Herzi, D., Morales-Martínez, A., Hernández-Verdín, I., Houillier, C., Alentorn, A., & Hoang‐Xuan, K. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.03.012 · Cited by 17
Briest, F., Noerenberg, D., Hennch, C., Yoshida, K., Hablesreiter, R., Nimo, J., Sasca, D., Kirchner, M., Mansouri, L., Inoue, Y., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02013-9 · Cited by 17
Self-citationLong Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization
Cascione, L., Giudice, L., Ferraresso, S., Marconato, L., Giannuzzi, D., Napoli, S., Bertoni, F., Giugno, R., & Aresu, L. (2019) · Non-Coding RNA · doi:10.3390/ncrna5030047 · Cited by 17
Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR
Niu, J., Ma, Z., Nuerlan, A., Li, S., Cui, W., Gao, H., Abulajiang, G., Zhang, W., & Li, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11186 · Cited by 17
Pillonel, V., Juškevičius, D., Bihl, M., Stenner, F., Halter, J. P., Dirnhofer, S., & Tzankov, A. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1786560 · Cited by 17
Isaev, K., Ennishi, D., Hilton, L. K., Skinnider, B., Mungall, K., Mungall, A. J. J., Bakhtiari, M., Tremblay‐LeMay, R., Silva, A., Ben‐Neriah, S., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.255950 · Cited by 17
Self-citationApostolidis, J. P., Sayyed, A., Darweesh, M., Kaloyannidis, P., & Hashmi, H. A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9350272 · Cited by 17
Diagnosis and treatment of lymphomas in the era of epigenetics
Chebly, A., Chouery, É., Ropio, J., Kourié, H. R., Beylot-Barry, M., Merlio, J., Tomb, R. R., & Chevret, E. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100782 · Cited by 17
Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
Qin, Y., Jiang, S., Liu, P., Yang, J., Yang, S., He, X., Zhou, S., Gui, L., Lin, J., Du, X., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s269624 · Cited by 17
SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence
Gao, J., Sidiropoulou, E., Walker, I. G., Krupka, J. A., Mizielinski, K., Usheva, Z., Samarajiwa, S., & Hodson, D. J. (2021) · Blood · doi:10.1182/blood.2020010432 · Cited by 17
Self-citationWang, Z., Ran, X., Qian, S., Hou, H., Dong, M., Wu, S., Ding, M., Zhang, Y., Zhang, X., Zhang, M., et al. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108998 · Cited by 17
CD24 is a surrogate for ‘immune‐cold’ phenotype in aggressive large B‐cell lymphoma
Higashi, M., Momose, S., Takayanagi, N., Tanaka, Y., Anan, T., Yamashita, T., Kikuchi, J., Tokuhira, M., Kizaki, M., & Tamaru, J. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.266 · Cited by 17
Lymphoma accelerates T cell and tissue aging
Hesterberg, R. S., Davis, J. T., Handoo, K. J., Elmarsafawi, A. G., Augello, A. C., Cheng, C., Atkins, R. M., Lee, D. H., Yang, C., Yao, J., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.023 · Cited by 16
Self-citationClinicopathological features of HCV-positive splenic diffuse large B cell lymphoma
Shimono, J., Miyoshi, H., Arakawa, F., Yamada, K., Sugio, T., Miyawaki, K., Eto, T., Miyagishima, T., Kato, K., Nagafuji, K., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03628-8 · Cited by 16
Lim, J. H., Wang, J. Q., Webb, F., Saxena, K., Tuipulotu, D. E., Pandey, A., Man, S. M., & Talaulikar, D. (2022) · iScience · doi:10.1016/j.isci.2022.104856 · Cited by 16
Self-citationZanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
Yuan, X., Li, X., Huang, Y., Jin, X., Liu, H., Zhao, A., Zhang, W., Qian, W., & Liang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1015081 · Cited by 16
Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome
Negara, I., Tomuleasa, C., Buruiana, S., & Efremov, D. G. (2024) · Cancers · doi:10.3390/cancers16122170 · Cited by 16
Schultheiß, C., Paschold, L., Mohebiany, A. N., Escher, M., Kattimani, Y. M., Müller, M., Schmidt-Barbo, P., Mensa‐Vilaró, A., Aróstegui, J. I., Boursier, G., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl3975 · Cited by 16
Guan, X., Wang, Y., Fang, T., Wang, J., Li, R., Hao, M., & Qiu, L. (2024) · Haematologica · doi:10.3324/haematol.2024.285304 · Cited by 16
Self-citationThe Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma
Koumpis, E., Georgoulis, V., Papathanasiou, K., Papoudou‐Bai, A., Kanavaros, P., Kolettas, E., & Hatzimichael, E. C. (2024) · Biomedicines · doi:10.3390/biomedicines12122658 · Cited by 16
Senescence-associated lineage-aberrant plasticity evokes T-cell-mediated tumor control
Belenki, D., Richter‐Pechańska, P., Shao, Z., Bhattacharya, A., Lau, A., de Freitas, J. A. N. L. F., Kandler, G., Hick, T., Cai, X., Scharnagl, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57429-x · Cited by 16
Ouyang, W., Lai, Z., Huang, H., & Li, L. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10030-w · Cited by 16
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study
Collinge, B. J., Hilton, L. K., Wong, J., Alduaij, W., Ben‐Neriah, S., Slack, G. W., Farinha, P., Boyle, M., Meissner, B., Cook, J. R., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016651 · Cited by 16
Self-citationPrognostication with circulating tumor DNA: is it ready for prime time?
Kurtz, D. M. (2019) · Hematology · doi:10.1182/hematology.2019000013 · Cited by 16
Wang, D., Zhang, Y., & Che, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01180 · Cited by 16
Zhang, W., Li, Y., Guan, Y., Shen, K., Zhang, M. L., Cai, H., Wang, J. C., Wang, Y., Huang, L., Cao, Y., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07198-1 · Cited by 16
Self-citationOrgueira, A. M., Ferro, R. F., Arias, J. Á. D., Santos, C. A., Rodríguez, B. A., Pérez, L. B., Vence, N. A., López, Á. B., Blanco, A. A., Valentín, P. M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248886 · Cited by 16
EGR1 Addiction in Diffuse Large B-cell Lymphoma
Kimpara, S., Lü, L., Hoang, N. M., Zhu, F., Bates, P. D., Daenthanasanmak, A., Zhang, S., Yang, D. T., Kelm, A., Liu, Y., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0267 · Cited by 16
Kaji, D., Kusakabe, M., Sakata‐Yanagimoto, M., Makishima, K., Suehara, Y., Hattori, K., Ota, Y., Mitsuki, T., Yuasa, M., Kageyama, K., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17824 · Cited by 16
Montesinos‐Rongen, M., Brunn, A., Sánchez-Ruiz, M., Küppers, R., Siebert, R., & Deckert, M. (2021) · Cancers · doi:10.3390/cancers13246334 · Cited by 16
Chen, X., Hu, Y., Su, W., Yang, S., Wang, X., Zhang, P., Hong, X., Liang, C., Qian, Z., Li, Z., et al. (2022) · 癌症:英文版 · doi:10.1002/cac2.12344 · Cited by 16
Georges, R. O., Sepúlveda, H., Angel, J. C., Johnson, E., Palomino, S., Nowak, R. B., Desai, A. B., López-Moyado, I. F., & Rao, A. (2022) · Nature Communications · doi:10.1038/s41467-022-33742-7 · Cited by 16
Gao, X., Kady, N., Wang, C., Abdelrahman, S., Gann, P. H., Sverdlov, M. S., Wolfe, A., Brown, N. A., Reneau, J. C., Robida, A. M., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0336 · Cited by 16
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
Mondello, P., Paludo, J., Novak, J. P., Wenzl, K., Yang, Z.-Z., Jalali, S., Krull, J. E., Braggio, E., Dasari, S., Manske, M. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2215 · Cited by 16
Mohammadnezhad, L., Azgomi, M. S., Manna, M. P. L., Guggino, G., Botta, C., Dieli, F., & Caccamo, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098385 · Cited by 16
Gibson, S. E., Dojcinov, S. D., Dotlić, S., Hartmann, S., Hsi, E. D., Klimkowska, M., Melle, F., Pileri, S. A., Ramsower, C. A., Rech, K. L., et al. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03550-5 · Cited by 16
Self-citationPrimary central nervous system lymphoma: Novel precision therapies
Mondello, P., Mian, M., & Bertoni, F. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.009 · Cited by 16
Nissen, M. D., Kusakabe, M., Wang, X., Simkin, G. O., Gracias, D., Tyshchenko, K., Hill, A., Meskas, J., Hung, S. S., Chavez, E. A., et al. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23919 · Cited by 16
Self-citationZhang, Y., & Zhou, D. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000844 · Cited by 16
Enhancing venetoclax activity in hematological malignancies
Satta, T., & Grant, S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1789588 · Cited by 16
DNA Copy Number Changes in Diffuse Large B Cell Lymphomas
Cascione, L., Aresu, L., Baudis, M., & Bertoni, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584095 · Cited by 16
Vitreoretinal Lymphoma: A Literature Review and Introduction of a New Diagnostic Method
Takhar, J. S., Doan, T. A., & Gonzales, J. A. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000365 · Cited by 16
L’Imperio, V., Morello, G., Vegliante, M. C., Cancila, V., Bertolazzi, G., Mazzara, S., Belmonte, B., Mangogna, A., Balzarini, P., Corral, L., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149746 · Cited by 16
Novel molecular classifications of DLBCL
Dubois, S., & Jardin, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0041-z · Cited by 16
Metadata
- Authors
- Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., Hodson, D. J., Xiao, W., Yu, X., Yang, Y., Zhao, H., Xu, W., Liu, X., Zhou, B., Du, W., Chan, W. C., Jaffe, E. S., Gascoyne, R. D., Connors, J. M., Campo, E., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Delabie, J., Rimsza, L. M., Tay Kuang Wei, K., Zelenetz, A. D., Leonard, J. P., Bartlett, N. L., Tran, B., Shetty, J., Zhao, Y., Soppet, D. R., Pittaluga, S., Wilson, W. H., & Staudt, L. M.
- Affiliations
- National Cancer Institute (US)
- National Institutes of Health (US)
- City Of Hope National Medical Center (US)
- BC Cancer Agency (CA)
- From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer...
- University of Würzburg (DE)
- Robert Bosch Hospital (DE)
- University Health Network (CA)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Alliance for Clinical Trials in Oncology (US)
- Washington University in St. Louis (US)
- Frederick National Laboratory for Cancer Research (US)
- ORCID
- Schmitz, Roland
- Wright, George W.
- Huang, Da Wei
- Phelan, James D.
- Wang, James Q.
- Roulland, Sandrine
- Kasbekar, Monica
- Young, Ryan M.
- Shaffer, Arthur L.
- Hodson, Daniel J.
- Xiao, Wenming
- Yu, Xin
- Yang, Yandan
- Zhao, Hong
- Zhou, Bin
- Chan, Wing C.
- Jaffe, Elaine S.
- Gascoyne, Randy D.
- Connors, Joseph M.
- Rosenwald, Andreas
- Ott, German
- Delabie, Jan
- Rimsza, Lisa M.
- Zelenetz, Andrew D.
- Leonard, John P.
- Bartlett, Nancy L.
- Tran, Bao
- Shetty, Jyoti
- Zhao, Yongmei
- Pittaluga, Stefania
- Wilson, Wyndham H.
- Staudt, Louis M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-12
- Volume
- 378
- Issue
- 15
- Pages
- 1396-1407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6010183
- OpenAlex
- W2797584152
- Cited by
- 2,241
- References
- 30
- Citations by year
- 2026: 193 · 2025: 271 · 2024: 320 · 2023: 339 · 2022: 317 · 2021: 302 · 2020: 250 · 2019: 191 · 2018: 53
- FWCI
- 153.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures (SPECS II) grant (5U01CA157581-05)
- Intramural Research Program of the NIH, National Cancer Institute
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- diffuse large B-cell lymphoma, genetic subtypes, B cell receptor signaling, NOTCH1 mutation, NOTCH2 mutation, EZH2 mutation, BCL2 translocation, CD79B mutation, germinal center B-cell-like lymphoma, therapeutic vulnerabilities, precision medicine, survival outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Biopsy, Genotype, Humans, Mutation, Prognosis, Lymphoma, Large B-Cell, Diffuse, Sequence Analysis, DNA, Genetic Heterogeneity, Gene Expression Profiling, Epigenesis, Genetic, Kaplan-Meier Estimate, Transcriptome, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.